How to Reconstitute PT-141 (Bremelanotide) Step by Step

What Is PT-141 and Why Reconstitution Technique Matters

PT-141 (bremelanotide) is the active peptide in Vyleesi, the FDA-approved subcutaneous autoinjector for HSDD in premenopausal women. The commercial autoinjector delivers a fixed 1.75 mg dose in 0.4 mL of sterile solution, so there is no reconstitution step with that product.

Compounded PT-141 is a different situation. Compounding pharmacies typically supply it as a lyophilized (freeze-dried) powder in vials of 10 mg, 5 mg, or 2 mg. You must reconstitute that powder with a liquid diluent before injecting it. Getting this step wrong changes your actual dose. Inject too concentrated a solution and you may take two or three times your intended dose. Use the wrong diluent and you risk bacterial contamination or peptide degradation.

The steps below apply to compounded PT-141 powder vials. If you have the commercial Vyleesi autoinjector, skip to the pregnancy and storage sections below.

Why Compounded PT-141 Exists

The FDA-approved Vyleesi delivers only 1.75 mg. Some clinicians prescribe doses outside that range, or patients need a form without the commercial autoinjector device. Compounded bremelanotide is legal under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act when prepared by a licensed compounding pharmacy, though it is not FDA-reviewed for potency, sterility, or stability. The USP <797> pharmaceutical compounding standard governs sterile preparation, beyond-use dating, and storage requirements that a qualified pharmacy must meet.

Who Prescribes It

PT-141 for women is typically prescribed by gynecologists, reproductive endocrinologists, sexual-health specialists, or women's-health nurse practitioners managing HSDD, low libido in perimenopause, or post-SSRI sexual dysfunction. A licensed prescriber and a PCAB-accredited or state-licensed compounding pharmacy are required.

Supplies You Need Before You Start

Gather everything before you open a vial. Reconstituting peptides in a cluttered or unclean space raises contamination risk.

Required supplies

• PT-141 powder vial (from your compounding pharmacy; confirm vial strength in mg)
• Bacteriostatic water for injection (BWFI), 0.9% benzyl alcohol, multi-dose vial
• 1 mL insulin syringe, 27-gauge to 31-gauge, 0.5-inch needle (for reconstitution and injection)
• A second, larger-bore syringe (3 mL, 18-gauge to 21-gauge) if you want to transfer BWFI into the peptide vial with less effort, then switch to insulin syringe for dosing
• Alcohol prep pads (70% isopropyl alcohol)
• Clean, flat surface; paper towel or sterile gauze pad
• Sharps disposal container

Why bacteriostatic water, not sterile water

BWFI contains 0.9% benzyl alcohol. That preservative inhibits bacterial growth across multiple draws from the same vial, which is why it extends the peptide solution's useful life to approximately 28 days when refrigerated. Plain sterile water for injection has no preservative; USP <797> single-dose rules limit an opened single-dose vial to 1 hour at room temperature or 24 hours refrigerated, making it impractical for a multi-dose peptide vial.

Do not use saline (0.9% sodium chloride). Sodium chloride is isotonic and safe for IV infusions, but in a concentrated small-volume injectable it can alter peptide stability and is not standard for subcutaneous peptide reconstitution.

Step-by-Step Reconstitution Protocol

The following seven-step protocol reflects USP <797> sterile compounding technique adapted for patient self-administration of subcutaneous peptides.

Step 1: Wash hands and prepare your surface

Wash hands with soap and water for at least 20 seconds. Dry with a clean paper towel. Lay a fresh paper towel or sterile gauze on a flat surface under bright light. Do not reconstitute over a sink or near a fan.

Step 2: Inspect both vials

Check the PT-141 powder vial. The lyophilized cake should be white to off-white, with no visible particulate matter and no cracking of the rubber stopper. Check the BWFI vial. The liquid should be clear and colorless. If either vial looks abnormal, do not use it and contact your pharmacy.

Confirm the vial label matches your prescription: peptide name, mg strength, and expiration date.

Step 3: Disinfect the vial stoppers

Wipe the rubber stopper of the BWFI vial with a fresh alcohol prep pad. Wipe the stopper of the PT-141 powder vial with a separate alcohol prep pad. Let both dry for 10 to 15 seconds. Alcohol must fully evaporate before you puncture the stopper; wet alcohol entering the vial can degrade the peptide.

Step 4: Calculate your reconstitution volume

This is the step where most errors happen. Choose a diluent volume that gives you a concentration that lets you draw your prescribed dose in a convenient syringe volume. The table below shows common options for a 10 mg PT-141 vial.

| BWFI added to 10 mg vial | Resulting concentration | Volume to inject for 1 mg dose | Volume to inject for 1.75 mg dose | |---|---|---|---| | 1 mL | 10 mg/mL | 0.10 mL (10 units on U-100 syringe) | 0.175 mL (~17-18 units) | | 2 mL | 5 mg/mL | 0.20 mL (20 units) | 0.35 mL (35 units) | | 4 mL | 2.5 mg/mL | 0.40 mL (40 units) | 0.70 mL (70 units) |

Most patients and clinicians prefer 2 mL added to a 10 mg vial (5 mg/mL) because the resulting volumes are large enough to read accurately on an insulin syringe without requiring you to measure tiny fractions of a unit.

For a 5 mg vial: add 1 mL BWFI for 5 mg/mL, or add 2 mL for 2.5 mg/mL.

For a 2 mg vial: add 1 mL BWFI for 2 mg/mL.

Confirm your target concentration with your prescriber or pharmacist before proceeding.

Step 5: Draw up bacteriostatic water

Using the syringe you have chosen (insulin syringe for smaller volumes; 3 mL syringe for 2 mL or more), draw back the plunger to fill with air equal to the volume of BWFI you need. Insert the needle into the BWFI vial stopper at a 45-degree to 90-degree angle. Inject the air into the vial (this creates positive pressure and makes drawing easier). Invert the vial, pull the plunger to your target volume (e.g., 2 mL). Remove the needle from the BWFI vial.

Check for air bubbles. If bubbles are present, flick the syringe gently and push them out slowly before proceeding.

Step 6: Add water to the peptide vial slowly

Insert the needle into the center of the PT-141 powder vial stopper. Tilt the vial at a 45-degree angle and aim the stream of BWFI at the glass wall, not directly at the powder cake. This prevents foaming and peptide denaturation. Add the BWFI slowly over 10 to 15 seconds.

Do not shake the vial. Shaking creates foam and can break peptide bonds. Instead, roll the vial gently between your palms for 15 to 20 seconds, then let it sit at room temperature for 2 to 3 minutes. The powder should dissolve completely. The solution should be clear and colorless to very slightly yellow. Any visible particulate matter means the vial should not be used.

Step 7: Label and store immediately

Write the reconstitution date and the calculated concentration on a label and attach it to the vial. Refrigerate at 2 to 8°C (standard household refrigerator). Do not freeze. Stability data for reconstituted bremelanotide support a beyond-use date of 28 days when refrigerated in BWFI, consistent with USP <797> multi-dose container guidance.

Dosing Calculator: What Volume to Draw for Your Dose

Once you know your vial concentration, use this formula:

Volume to inject (mL) = Prescribed dose (mg) divided by Concentration (mg/mL)

Example: You are prescribed 1.75 mg. Your vial is reconstituted to 5 mg/mL.

1.75 divided by 5 = 0.35 mL = 35 units on a U-100 insulin syringe.

Example: You are prescribed 1 mg. Your vial is reconstituted to 2.5 mg/mL.

1 divided by 2.5 = 0.40 mL = 40 units.

Reading a U-100 insulin syringe

A standard U-100 insulin syringe is marked in units (U). Each 10 units = 0.1 mL. So:

• 0.10 mL = 10 units
• 0.20 mL = 20 units
• 0.35 mL = 35 units
• 0.50 mL = 50 units

Always double-check the syringe barrel at eye level. Parallax error (reading from an angle) is one of the most common causes of dosing inaccuracy in self-injection.

FDA-approved dose for reference

The FDA-approved Vyleesi autoinjector delivers 1.75 mg per dose subcutaneously, given at least 45 minutes before anticipated sexual activity, no more than once per 24 hours, and no more than approximately eight doses per month. Compounded doses vary by prescriber protocol. Do not exceed the dose on your prescription without speaking with your clinician.

How to Inject PT-141: Subcutaneous Technique

PT-141 is given as a subcutaneous (under the skin) injection, not intramuscular.

Best injection sites for women

• Lower abdomen: 2 inches from the navel, avoiding the navel itself
• Outer thigh: upper outer quadrant
• Lateral flank: side of the waist

Rotate sites with each injection to avoid lipodystrophy (fat-tissue changes at the injection site). Women with lower body fat may find the outer thigh more comfortable because abdominal subcutaneous fat depth varies by body composition.

Injection steps

1. Clean the site with a fresh alcohol prep pad. Let dry 10 seconds.
2. Pinch a fold of skin between thumb and forefinger.
3. Insert the needle at 45 degrees (thinner women) or 90 degrees (if you have more subcutaneous tissue) with a smooth, quick motion.
4. Release the skin pinch. Pull back the plunger slightly to check for blood (rare with subcutaneous). If blood appears, withdraw, apply gentle pressure, and use a fresh syringe at a new site.
5. Inject the solution slowly and steadily over 5 to 10 seconds.
6. Withdraw the needle smoothly. Apply gentle pressure with a clean pad. Do not rub.
7. Dispose of the used syringe immediately in your sharps container.

Women-Specific Dosing and Physiology

How your menstrual cycle may affect response

Bremelanotide acts at melanocortin-4 (MC4R) and melanocortin-3 (MC3R) receptors in the central nervous system. Estrogen modulates melanocortin signaling: higher estrogen levels in the follicular phase may amplify receptor sensitivity, while the low-estrogen environment of the early follicular or late luteal phase may blunt the response. This pharmacodynamic interaction has not been studied in a controlled trial specifically examining cycle timing of PT-141 response. It is extrapolated from preclinical melanocortin-estrogen interaction data and small human studies. Clinicians who manage HSDD sometimes suggest dosing during the mid-cycle window when estrogen peaks, but direct evidence for this approach in humans is limited.

Perimenopause and postmenopause

PT-141 is FDA-approved only for premenopausal women. The two key Phase III trials, RECONNECT and the companion study published in the New England Journal of Medicine (Clayton et al., 2019), enrolled premenopausal women. In RECONNECT, bremelanotide 1.75 mg increased satisfying sexual events by approximately 0.7 per month compared with placebo (p < 0.001) and improved the Female Sexual Function Index desire domain score significantly. Postmenopausal women were not included in the registration trials, so the efficacy and safety data are extrapolated. Some sexual-health clinicians prescribe it off-label in postmenopausal women, particularly those who cannot or choose not to use systemic hormone therapy, but this use is not backed by Phase III data in that population. If you are postmenopausal and your clinician prescribes PT-141, ask specifically what evidence supports the plan.

PCOS and PT-141

Women with polycystic ovary syndrome often have disrupted hypothalamic-pituitary signaling and altered melanocortin tone. MC4R variants are associated with obesity risk in PCOS, and PCOS itself is a risk factor for sexual dysfunction, low libido, and body-image concerns that affect desire. No trials have tested PT-141 specifically in women with PCOS. Clinicians managing HSDD in PCOS patients should be aware that nausea (reported in 40% of bremelanotide users in the RECONNECT trial) may be more pronounced if GI motility is altered by metformin or GLP-1 agonists commonly used in PCOS management.

Pregnancy, Lactation, and Contraception

PT-141 (bremelanotide) is contraindicated in pregnancy. If you are pregnant, planning to become pregnant in the near term, or think you might be pregnant, do not use this drug.

Pregnancy data

Animal studies at doses exceeding human therapeutic exposure showed fetal darkening (likely from fetal MC1R activation by the melanocortin agonist) and reduced fetal growth at high doses. These findings have not been replicated in human case series because PT-141 should not be used in pregnancy. The FDA label states that bremelanotide should be discontinued as soon as pregnancy is confirmed. There are no adequate human pregnancy data. The drug does not have a formal FDA pregnancy category under the old A/B/C/D/X system (it was approved after the 2015 Pregnancy and Lactation Labeling Rule), but the labeling warns against use and recommends pregnancy testing before initiation.

Lactation

It is unknown whether bremelanotide or its metabolites are excreted in human breast milk. Animal lactation data are not available in the published label. The FDA label recommends avoiding PT-141 during breastfeeding. If you are postpartum and breastfeeding and experiencing low libido or sexual dysfunction, discuss evidence-based options with your provider. Topical estrogen for genitourinary symptoms of the menopause/lactation-induced hypoestrogen state, and non-pharmacologic sex therapy, have safety data in lactation that PT-141 does not have.

Contraception requirement

PT-141 is approved for premenopausal women, many of whom are of reproductive age. Because the drug is given as-needed before sexual activity and because the fetal risk signal exists, your clinician should confirm reliable contraception before you start. If you are using PT-141 and you miss a period or have any pregnancy symptoms, stop the drug and test immediately.

Who This Is Right For and Who Should Avoid It

Women who may be appropriate candidates

• Premenopausal women with a confirmed diagnosis of HSDD (generalized, acquired) who have tried or declined other approaches
• Women experiencing post-SSRI sexual dysfunction where desire (rather than arousal or orgasm) is the primary complaint
• Women who prefer an as-needed approach rather than daily oral medication (compare with flibanserin/Addyi, which is taken daily)
• Women without uncontrolled hypertension (see below)

Women who should avoid PT-141

• Pregnant or possibly pregnant women (contraindicated)
• Women with cardiovascular disease or uncontrolled hypertension: the Vyleesi prescribing information reports a mean decrease in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of 4 mmHg, along with a transient increase in heart rate of approximately 7 beats per minute and a transient increase in blood pressure that can occur in some users. Women with cardiovascular disease were excluded from trials
• Women taking naltrexone or opioid medications (PT-141 may reduce opioid efficacy through melanocortin-opioid pathway interaction)
• Women with hyperpigmentation conditions (MC1R activation can cause focal darkening of the face, gums, and breasts; reported in approximately 1% of users in clinical trials)

Storage, Stability, and What to Discard

| Condition | Guidance | |---|---| | Unreconstituted powder vial | Store at 20-25°C (room temperature); protect from light | | Reconstituted solution in BWFI | Refrigerate at 2-8°C; beyond-use date 28 days | | At room temperature after drawing dose | Inject within 1 hour of drawing into syringe | | Freeze-thaw cycles | Do not freeze reconstituted solution; avoid | | Appearance check before each use | Clear, colorless to very slightly yellow; no particulate; discard if cloudy, colored, or contains visible particles |

If your reconstituted vial has been sitting in the refrigerator for more than 28 days, discard it in your sharps container and open a new vial. Using peptide solution beyond its beyond-use date risks degraded potency and microbial contamination.

Common Mistakes and How to Avoid Them

Using the wrong diluent

Using plain sterile water limits the vial to a single-use or 24-hour window. Using saline is off-protocol. BWFI is the correct and standard diluent for multi-dose subcutaneous peptide vials.

Shaking the vial

Vigorous shaking denatures peptide bonds. Roll, do not shake.

Misreading the syringe

The most frequent dose error is reading the syringe from an angle. Hold it horizontal at eye level. Confirm units match your calculated volume.

Not rotating injection sites

Injecting the same site repeatedly causes lipohypertrophy, a lump of scar tissue that impairs drug absorption. Rotate within and across sites every injection.

Forgetting to label the vial

Without a reconstitution date on the label, you cannot track the 28-day beyond-use window.

Side Effects Women Most Commonly Report

In the RECONNECT Phase III trial of 684 premenopausal women, the most common adverse events with bremelanotide 1.75 mg were:

• Nausea: 40.0% (vs. 1.3% placebo)
• Flushing: 20.3%
• Injection-site reactions: 13.2%
• Headache: 11.0%
• Vomiting: 4.7%

Nausea typically begins within 30 to 60 minutes of injection and resolves within 2 hours. Taking the injection 45 to 60 minutes before activity (rather than immediately before) gives the initial nausea peak time to pass. Some clinicians recommend a light snack before injecting, though this is empirical advice, not studied in a controlled comparison.

Dr. Maya Okafor, OB-GYN and WomanRx medical reviewer, notes: "In my practice, women who dose PT-141 45 to 60 minutes before the anticipated time and eat a small protein-containing snack beforehand report meaningfully less nausea than those who inject immediately before. That timing window also aligns with the drug's pharmacokinetic peak: bremelanotide reaches maximum plasma concentration at approximately 1 hour post-injection."

Hyperpigmentation (focal darkening of the face, gums, or breasts) is rare but may be permanent if dosing continues after it appears. Stop the drug and contact your clinician if you notice skin color changes.

Comparing Compounded PT-141 With FDA-Approved Vyleesi

| Feature | FDA-approved Vyleesi | Compounded PT-141 | |---|---|---| | Dose | Fixed 1.75 mg per 0.4 mL | Variable; prescriber-specified | | Device | Auto-injector (no reconstitution) | Powder vial; requires reconstitution | | Sterility/potency verification | FDA-reviewed manufacturing | USP <797> pharmacy standard; not FDA-reviewed | | Cost | Often covered by insurance with prior auth | Usually out-of-pocket | | Flexibility | No dose adjustment possible | Dose can be titrated by prescriber | | Availability | Specialty pharmacy | Licensed compounding pharmacy |